Ann: ResApp Grants Option to Consumer Health Division of Sanofi, page-103

Feeling Perplexed.
Maybe Great to be involved with a giant like Sanofi, it depends on what, where, how in terms of exclusivity though. Ping An etc sidelined partly or wholly?.
They always indicated direct to consumer would be later. Now its flagged as possibly next year in some shape or form whatever that may be.

We can earn huge revenues via Sanofi’s global footprint but is that at the cost of less telehealth market involvement.?

Is this mainly attractive to management as Sanofi pay US20+ million as part of the contract or a justifiable sensible lucrative deal in its own right that wont draw raised eyebrows and frowns.?

What will they jointly develop?. Nothing but some smart envelope around our core technology or is it integrated with other AI technologies to give more power and accuracy in diagnosis?

Will the outcomes be something that can only be used by Sanofi customers or The RAP/Sanofi product is available to everyone including telehealth companies.?.
Is it truly a bait to get Apple and others to show their hands?.

Will potential telehealth and hospital customers hold off purchasing our product in the light of this announcement?.
Will this make our efforts in developing those ruggedised devices redundant?.

Great posts in here as the HC brains trust starts digesting it today and exploring these kinds of issues.Thanks for the insights so far.
Perplexed Fox